文献速递消化系统肿瘤

Encorafenib联合西妥昔单抗成为经治BRAF V600E突变mCRC新标准:BEACON研究更新生存及亚组分析

Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study.
PubMed 文献 · J Clin Oncol · 2021-01-01

BEACON CRC III期研究评估encorafenib联合西妥昔单抗(双联)或再联合binimetinib(三联)对比伊立替康/FOLFIRI联合西妥昔单抗,用于经1-2线治疗进展的BRAF V600E突变mCRC。更新分析显示双联和三联中位OS均为9.3个月,对照组5.9个月(双联HR 0.61,三联HR 0.60);确认ORR双联19.5%、三联26.8%、对照组1.8%。结论认为encorafenib联合西妥昔单抗改善OS、ORR和PFS,成为新标准治疗。

要点

  • 双联和三联中位OS均9.3个月,优于对照组5.9个月(HR 0.61/0.60)。
  • 确认ORR:双联19.5%、三联26.8%、对照组1.8%。
  • ≥3级不良事件发生率双联57.4%、三联65.8%、对照组64.2%。

核心结论

  • Encorafenib联合西妥昔单抗改善经治BRAF V600E突变mCRC的OS、ORR和PFS,成为新标准治疗。

研究设计与样本

  • 开放标签III期BEACON CRC研究,665例BRAF V600E突变mCRC患者按1:1:1随机接受三联、双联或对照。
  • 主要终点为三联对比对照的OS和独立审查ORR;双联对比对照的OS为关键次要终点。
  • 更新分析增加6个月随访,并报告所有随机化患者的ORR。

主要发现

  • 三联组(n=224)中位OS 9.3个月(95%CI 8.2-10.8),对照组(n=221)5.9个月(95%CI 5.1-7.1),HR 0.60(95%CI 0.47-0.75)。
  • 双联组(n=220)中位OS 9.3个月(95%CI 8.0-11.3),对比对照HR 0.61(95%CI 0.48-0.77)。
  • 确认ORR:三联26.8%(95%CI 21.1%-33.1%),双联19.5%(95%CI 14.5%-25.4%),对照1.8%(95%CI 0.5%-4.6%)。
  • ≥3级不良事件发生率:三联65.8%、双联57.4%、对照64.2%,与既往主要分析一致。

临床怎么用

  • 对于经1-2线治疗进展的BRAF V600E突变mCRC,可选用encorafenib联合西妥昔单抗双联方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: BEACON CRC evaluated encorafenib plus cetuximab with or without binimetinib versus investigators' choice of irinotecan or FOLFIRI plus cetuximab in patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC), after progression on 1-2 prior regimens. In the previously reported primary analysis, encorafenib, binimetinib plus cetuximab (ENCO/BINI/CETUX; triplet) and encorafenib plus cetuximab (ENCO/CETUX; doublet) regimens improved overall survival (OS) and objective response rate (ORR; by blinded central review) versus standard of care. The purpose of this analysis was to report updated efficacy and safety data. METHODS: In this open-label, phase III trial, 665 patients with BRAF V600E-mutant mCRC were randomly assigned 1:1:1 to receive triplet, doublet, or control. Primary end points were OS and independently reviewed ORR comparing triplet to control. OS for doublet versus control was a key secondary end point. Updated analyses include 6 months of additional follow-up and ORR for all randomized patients. RESULTS: Patients received triplet (n = 224), doublet (n = 220), or control (n = 221). Median OS was 9.3 months (95% CI, 8.2 to 10.8) for triplet and 5.9 months (95% CI, 5.1 to 7.1) for control (hazard ratio [HR], 0.60 [95% CI, 0.47 to 0.75]). Median OS for doublet was 9.3 months (95% CI, 8.0 to 11.3) (HR v control, 0.61 [95% CI, 0.48 to 0.77]). Confirmed ORR was 26.8% (95% CI, 21.1% to 33.1%) for triplet, 19.5% (95% CI, 14.5% to 25.4%) for doublet, and 1.8% (95% CI, 0.5% to 4.6%) for control. Adverse events were consistent with the prior primary analysis, with grade ≥ 3 adverse events in 65.8%, 57.4%, and 64.2% for triplet, doublet, and control, respectively. CONCLUSION: In the BEACON CRC study, encorafenib plus cetuximab improved OS, ORR, and progression-free survival in previously treated patients in the metastatic setting compared with standard chemotherapy. Based on the primary and updated analyses, encorafenib plus cetuximab is a new standard care regimen for previously treated patients with BRAF V600E mCRC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Tabernero J, Grothey A, Van Cutsem E, et al. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. J Clin Oncol. 2021. PMID: 33503393. doi:10.1200/JCO.20.02088

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。